IN8bio (INAB) Corporate presentation summary

Company overview and team

• Clinical-stage biotech focused on gamma-delta (γδ) T cell therapies for cancer and autoimmune diseases.

• Team has 35+ years of γδ T cell expertise and deep experience in oncology, immunology, product development, and commercialization.

Platform and technology

• Single platform addresses both cancer and autoimmune diseases by resetting or enhancing immune responses.

• γδ T cells combine innate and adaptive immune functions, offering potent, durable, and safer responses without genetic engineering.

• Higher γδ T cell levels in tumors correlate with improved survival and treatment responses.

Pipeline and clinical programs

• Pipeline includes T cell engagers (TCEs) and cellular therapies for leukemia (INB-100), solid tumors (INB-200/400), and autoimmune diseases (INB-619).

• INB-619 is a pan-γδ CD19 TCE that expands both Vδ1+ and Vδ2+ γδ T cell subtypes, efficiently depletes B cells, and avoids CD3-driven toxicities.

• INB-100 shows dose-dependent expansion of γδ T cells post-transplant, with improved progression-free and overall survival in AML patients.

• INB-200/400 for glioblastoma (GBM) demonstrates repeat dosing leads to longer progression-free and overall survival, with strong immune infiltration and tumor remodeling.